DUBLIN--(BUSINESS WIRE)--The "Vaccines Market By Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR), Type (Live, Toxoid), Route Of Administration (IM, SC, Oral), Valence (Monovalent, Multivalent) & Geography - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global vaccines market is expected to reach $57.50 billion by 2025 from $33.70 billion in 2018, growing at a CAGR of 7.9%
The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market.
However, the high costs associated with vaccine development, stringent regulations and a longer timeline for vaccine development, as well as product recalls, are expected to hinder the growth of this market to a certain extent. On the other hand, the new product development cycle for vaccines and need for more training dedicated to vaccinology pose a major challenge for vaccines industry.
The key players profiled in the global vaccines market research report are GSK, Merck & Co., Inc., Pfizer, Sanofi, CSL Limited, Emergent Biosolutions, Johnson and Johnson, Serum Institute of India, Daiichi Sankyo, Takeda, and AstraZeneca.
Scope of the Report:
Market by Indication
- Pneumococcal Disease
- Meningococcal Disease
Market by Route of Administration
- Intramuscular (IM
- Subcutaneous (SC/SQ)
- Others (Intradermal and Nasal)
Market by Type
- Subunit, recombinant, polysaccharide, and conjugate vaccines
- Inactivated vaccines
- Live-attenuated vaccines
- Toxoid vaccines
Market by Valent
For more information about this report visit https://www.researchandmarkets.com/research/q5hhks/vaccines_market?w=4